Profile picture

Doctor Joao Fernandes Pedro

Santa Maria Hospital - CHULN, Lisbon (Portugal)
Follow
Logo ESC

Contributor content

Polypharmacy as an independent predictor of heart failure hospitalization and mortality in HFrEF patients
Presentation
Polypharmacy as an independent predictor of heart failure hospitalization and mortality in HFrEF patients
Read more
Expanding the role of myosin inhibition: mavacamten in apical hypertrophic cardiomyopathy with mid-ventricular obstruction
Presentation
Expanding the role of myosin inhibition: mavacamten in apical hypertrophic cardiomyopathy with mid-ventricular obstruction
Read more
The genetic blueprint behind PAH clinical features and prognosis
Presentation
The genetic blueprint behind PAH clinical features and prognosis
Read more
Early-onset ischemic heart disease with massive thrombosis: diagnostic and therapeutic dilemmas
Presentation
Early-onset ischemic heart disease with massive thrombosis: diagnostic and therapeutic dilemmas
Read more
Real-World incidence and risk factors for osimertinib-associated cardiotoxicity
Presentation
Real-World incidence and risk factors for osimertinib-associated cardiotoxicity
Read more
When sPESI falls short: the msPESI raises the bar in pulmonary embolism risk stratification
Presentation
When sPESI falls short: the msPESI raises the bar in pulmonary embolism risk stratification
Read more
Takotsubo syndrome in real-world practice: a tertiary centre case series
Presentation
Takotsubo syndrome in real-world practice: a tertiary centre case series
Read more
Risk stratification after Takotsubo syndrome: long-term prognostic predictors
Presentation
Risk stratification after Takotsubo syndrome: long-term prognostic predictors
Read more
Inflammation meets genetics: unleashing an electrical storm
Presentation
Inflammation meets genetics: unleashing an electrical storm
Read more
Real-world impact of intermittent levosimendan on survival, hospitalizations, and healthcare costs in advanced heart failure
Presentation
Real-world impact of intermittent levosimendan on survival, hospitalizations, and healthcare costs in advanced heart failure
Read more

ESC 365 is supported by

novartis Explore sponsored resources